Due Diligence of Dossier Assistance
Optimize Your Path to Regulatory Success with Expert Due Diligence Services, from Comprehensive Dossier Reviews to Strategic Guidance
Get precision in compliance by our Due Diligence of Dossier Assistance
We serve complete due diligence services for pharmaceutical products, ensuring regulatory compliance, mitigating risks, and optimizing dossier approval chances. Our expertise helps your company navigate the complex regulatory landscape confidently, achieving your regulatory goals effectively, thereby enhancing your chances of successful dossier approval.
- Overview
Pharmaceutical and biotechnology corporations are increasingly shifting their approach from R&D to commercialization as development costs and timelines continue to rise. Product acquisition and licensing have become preferred strategies to reduce R&D expenditure and accelerate time to market. Due diligence is the initial phase of acquisition, focused on identifying potential regulatory risks during registration or commercialization in line with ICH guidelines.
Zenovel provides structured technical due diligence assistance to pharmaceutical companies, distributors, and start-ups during the early evaluation phase of licensing discussions. Our assessment emphasizes regulatory and CMC requirements, lifecycle maintenance considerations, and risk-based gap analysis to support informed acquisition decisions and successful commercialization outcomes.
- Our Key Features of templates
- Why Choose Zenovel ?
- Proven Expertise
We assist you in effectively navigating the intricate regulatory landscape by our thorough industry knowledge and experience.
- Cost and Time Efficiency
Our assistance in the acquisition phase and commercialization focus helps reduce R&D expenditure and expedite product time to market.
- Expert Precision in Compliance
Our services guarantee strict adherence to regulatory standards, reducing risks and enhancing the likelihood of successful dossier approval.
People Also Ask (FAQs)
Regulatory dossier due diligence is a comprehensive scientific and regulatory review of submission documents conducted through dossier due diligence services. The review evaluates the completeness, accuracy, regulatory compliance, and potential risks associated with a CTD or eCTD regulatory dossier. This process helps pharmaceutical companies identify documentation gaps and regulatory risks before product acquisition, licensing agreements, partnerships, or regulatory submissions.
Pharmaceutical dossier due diligence services help companies minimize regulatory and commercial risks when acquiring or licensing products. A detailed regulatory dossier review identifies missing or non-compliant documentation, evaluates data integrity and scientific quality, and assesses alignment with regulatory requirements from authorities such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and CDSCO. This evaluation also helps estimate approval timelines and potential regulatory queries, enabling informed investment and licensing decisions.
A regulatory dossier due diligence review typically covers all modules of the Common Technical Document (CTD/eCTD). This includes administrative and regional information, quality (CMC) documentation, non-clinical studies, clinical study reports, stability data, bioequivalence studies where applicable, labeling information, and risk management plans. Conducting a structured CTD dossier review service ensures regulatory completeness and submission readiness.
Yes, Zenovel identifies high-risk areas such as missing data, inconsistencies, and non-compliance with regulatory guidelines, ensuring early issue resolution.
Zenovel delivers detailed reports with actionable insights and practical recommendations to strengthen your dossier before submission.
Blogs and news
Our Latest Article
Introduction to Generic Inhalation Product Development Inhalation products pose significant challenges in generic drug development due to the complexity of formulations and device technology, making bioequivalence more difficult to establish compared to conventional oral dosage forms. Examples include Albuterol MDIs (metered dose inhalers), DPIs Dry Powder Inhalers, and nebulized therapies,
India is a significant player in the global pharmaceuticals sector, characterized by a diverse population and cost-effective infrastructure. However, its potential in clinical research is hindered by complex regulatory challenges that delay innovations and deter investment, affecting the timely market introduction of life-saving drugs. This blog discusses the major obstacles
The FDA issued 466 Form 483s to drug organizations in FY 2022, more than double the previous year, highlighting significant quality failures in the pharmaceutical sector. For startups and scale-ups seeking market approval, the excitement of innovation often conflicts with the strict requirements of current good manufacturing practices (cGMP). Although
Introduction Liposomal Amphotericin-B is a critical antifungal medication that requires careful attention during Bioequivalence (BE) studies. These studies aim to demonstrate the similarity of a generic liposomal Amphotericin B formulation to the reference drug in terms of pharmacokinetics. Zenovel, with its extensive experience in monitoring Amphotericin B studies, can play
In the pharmaceutical and biotechnology industries, obtaining regulatory approval is essential prior to introducing new drugs or biologics to the market. A pivotal aspect of this approval process is the FDA Pre-Approval Inspection (PAI), which involves a comprehensive assessment of manufacturing facilities, processes, and data integrity to ensure adherence to
Risk Based Monitoring (RBM) is a more efficient alternative to traditional clinical trials, focusing on high-risk areas through data-driven insights. It ensures patient safety, data integrity, and regulatory compliance while reducing costs and timelines. However, the success of RBM depends on the competency of monitors, who identify risks, analyze data,
